Vesalius Medical Technologies is a privately held company incorporated in 2009 in Belgium, where many multinational medical device companies maintain subsidiaries.
Vesalius Medical Technologies offers a unique combination of a strong and experienced engineering background with renowned and expert surgeons providing in-depth know-how in the orthopedic and oncological field.
Vesalius Medical Technologies opts for unique ablation solutions that provide a high added value to existing non-resolved medical challenges resulting in reliable and cost-effective devices. Vesalius Medical Technologies has the know-how, engineering and medical expertise in-house and creates unique solutions that provide a high added value to existing non-resolved medical challenges resulting in reliable and cost-effective devices.
Furthermore, Vesalius Medical Technologies teams up with the best of class specialist in the field of Intellectual Property, Legal advice, Clinical trials, Engineering and Production, complementing their own know-how resulting in a lean and most cost-effective structure.
ABLAflex™ provides a minimally invasive procedure for the treatment of chronic bursitis that has important advantages over actual standard of care. ABLAflex™ is currently under clinical investigation and is not commercially available.
Next to the ABLAflex™ procedure, Vesalius' Research and Development has resulted in a globally protected novel Radiofrequency ablation (RFA) invention, resolving current RFA challenges by yielding reliable coagulation adaptable to any size or shape diseased tissue.